Overview

WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Werewolf Therapeutics, Inc.